KPE – C- 022 KPE’s Certificate Program in Biologic (Biotech & Biosimilar) Regulation & Strategic Management
Posted on18 Sep 2014
Comments0
Course Flow and Timeline
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Executive Program
- Advance Diploma Program
- Advance Diploma Dual Specialization
- Certificate Courses – 1 Month
- Biotech Regulatory Affairs & Strategic Management
- Pharma Product Management
- Pharma Project Management
- Medical Devices Regulation
- Drug Regulatory Affairs
- Latam DRA
- African DRA
- GCC Regulatory Affairs
- ASEAN DRA
- European DRA
- USFDA Regulation
- GMP & GMP Audit
- Dossier Training
- Drug Discovery to Commercialization
- QA Documentation
- IP Management
- Short Courses / Books / White Paper
- Admission Process
- Knowledge Base
- Contact
KPE – C- 022 KPE’s Certificate Program in Biologic (Biotech & Biosimilar) Regulation & Strategic Management
Our Popular Courses
Recent Articles
- Bristol-Myers Squibb to acquire Celgene in deal worth $74 billion
- Pfizer and GlaxoSmithKline to merge consumer healthcare units
- Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
- Boehringer Ingelheim’s ASF COMBAT market launch: East to use Tool in prevention of African swine fever
- 2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
- 2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
- US FDA approves Supernus’ sNDA to expand Oxtellar XR label
- Is it always New molecule is first approved in USFDA, instead of the EU approval?
- AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
- Novartis app for opium addicts gets US approval